-
Health Quality Agency: Vaccines Safe, Adverse Effects Rare
1 July 2014. The Agency for Healthcare Research and Quality, a division of the U.S. Department of Health and Human Services, issued a report today indicating a systematic review of published research shows that vaccines are safe and serious adverse reactions to vaccines are rare occurrences. The study, conducted by the Southern California Evidence-Based Practice…
-
Univ at Buffalo Starting Advanced Materials Research Center
1 July 2014. University at Buffalo in New York is establishing a new materials research department that aims to accelerate the process of bringing advanced materials to market. Buffalo’s Materials Design and Innovation department is a joint project of the university’s engineering and Arts and Science schools, and funded in part by donation of $1.5…
-
Online Clinical Trial with Children Tests Autism Therapy
30 June 2014. Researchers at University of California in San Francisco and Kennedy Krieger Institute in Baltimore completed a clinical trial conducted entirely online testing the ability of omega-3 fatty acids to control hyperactivity in children with autism. The team led by UC-San Francisco medical professor Stephen Bent published its findings in this month’s issue…
-
Spin-Off Licenses Genomic Technology from Wash. University
30 June 2014. PierianDx, a new company formed by medical faculty and practitioners at Washington University in St. Louis, licensed genomic technology from the university to commercialize diagnostic tools for personalized medicine. Financial details of the licensing deal were not disclosed. The start-up company plans to offer the technology in a system developed internally by…
-
Big Data Analytics ID People Risking Metabolic Syndrome
27 June 2014. Researchers from the insurance provider Aetna Inc. and GNS Healthcare, a data analytics company in the health care industry, developed statistical models that can identify population groups and individuals at risk for metabolic syndrome, a collection of conditions pointing to future heart disorders and diabetes. The team from Aetna’s Innovation Labs in…
-
FDA Approves Motorized Exoskeleton for Spinal Cord Injury
27 June 2014. The Food and Drug Administration yesterday cleared for sale in the U.S. a motorized exoskeleton system for people with lower-body paralysis from spinal cord injury. The device, called ReWalk, is made by Argo Medical Technologies in Marlborough, Massachusetts, and according to FDA, the first system of its kind approved to help people…
-
Late Trial Testing Topical Gel for Diabetic Nerve Pain
26 June 2014. A late-stage clinical trial testing a topical gel to treat diabetic nerve pain completed its enrollment, according to BioDelivery Sciences International in Raleigh, North Carolina, the study’s sponsor. The trial is the first of two clinical studies of Clonidine Topical Gel in preparation for the company’s new drug application with the U.S.…
-
Epoxy/Carbon Ink 3-D Printed into Lightweight Cell Material
26 June 2014. Engineers at Harvard University developed an ink made of epoxy resins and carbon fibers, which when arrayed into a cellular pattern with three-dimensional printing, can produce a strong lightweight composite with the properties of balsa wood. Materials scientist and engineering professor Jennifer Lewis and postdoctoral researcher Brett Compton, now at Oak Ridge…
-
Outpatient Safety Net Harnesses Electronic Health Data
25 June 2014. The Kaiser Permanente health plan in Southern California, headquartered in Pasadena, established a follow-up monitoring system for plan members visiting doctors’ offices or outpatient clinics that scans its electronic health records database for gaps in outpatient care. A team from Kaiser Permanente’s Southern California network, led by regional quality and clinical analysis…
-
Early Trial Shows Neural Regrowth Effects on Depression
25 June 2014. An early-stage clinical trial by Neuralstem Inc. in Germantown, Maryland provides evidence its experimental drug to treat major depressive disorder is having a positive impact on patients’ brain activity and behavior. The company reported the findings yesterday at a meeting of the International College of Neuropsychopharmacology in Vancouver, Canada, and last week…